Clot-Buster Doesn't Raise Bleeding Risk in Warfarin
THURSDAY, May 10 (HealthDay News) -- Tissue plasminogen
activator (tPA), a drug used to combat clots in stroke patients,
does not increase the risk of dangerous bleeding in patients also
taking the blood thinner warfarin, new research found.
The study included information on more than 23,000 ischemic
stroke patients treated with tPA at more than 1,200 U.S. hospitals.
Ischemic stroke, the most common type of brain attack, is caused by
a blocked blood vessel to the brain. The clot-busting drug tPA is
sold under the brand name Activase and the generic name
In the study, about 8 percent of the stroke patients were taking
the anticoagulant warfarin (Coumadin) before hospital
The researchers found little difference in the risk of severe
bleeding due to a brain hemorrhage in patients who received tPA
while on warfarin versus those not taking the blood-thinning drug.
The study also found no major differences in the patients' risks of
tPA-related complications or in-hospital death after tPA.
The research was scheduled to be presented on Thursday at the
American Heart Association's Quality of Care and Outcomes Research
meeting in Atlanta.
"Although it's the only drug approved by the U.S. Food and Drug Administration to treat acute ischemic stroke, tPA is underused among patients on home warfarin therapy mainly because of the fear that it will cause bleeding," study lead author Dr. Ying Xian, a research fellow at Duke Clinical Research Institute in Durham, N.C., said in a heart association news release.
The researchers noted that the patients taking warfarin were
usually older, had more illnesses and had more severe strokes than
those not on warfarin.
"Our study suggests tPA is not associated with excessive bleeding or death among warfarin patients when used according to American Heart Association/American Stroke Association guidelines," Xian said.
And, the researcher added, tPA "has been shown to minimize brain
damage and disability from stroke and should not be withheld from
The study authors pointed out that they didn't measure
functional, neurological or long-term results of tPA treatment.
The data and conclusions of research presented at medical
meetings should be viewed as preliminary until published in a
The U.S. National Stroke Association has more about
treatments for stroke.
Copyright © 2012
. All rights reserved.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.